Reviva Publishes Vocal Biomarker Data from RECOVER Phase 3 Clinical Trial of Brilaroxazine in Schizophrenia Treatment

Reviva Pharmaceuticals has published an article in Biological Psychiatry highlighting clinical vocal biomarker data from the RECOVER Phase 3 clinical trial of brilaroxazine for treating negative symptoms in schizophrenia. The findings reinforce brilaroxazine's treatment effect on negative symptoms and support the use of speech latency as an enrichment tool for clinical trials. The results show that speech latency can differentiate between patients with moderate-to-severe and low negative symptoms and can reduce sample-size needs and enhance trial outcomes.